Estimating Long Term Cost Savings from Treatment of Alzheimer’s DiseaseA Modelling Approach

被引：0
|
作者：
Paul Fenn
Alastair Gray
机构：
[1] University of Nottingham,The Business School
[2] Oxford Health Economics Research Centre,undefined
来源：
PharmacoEconomics | 1999年 / 16卷
关键词：
Adis International Limited; Rivastigmine; Tacrine; Baseline Severity; Weibull Shape Parameter;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: This paper puts forward a proposal for a modelling approach to the estimation of long term cost savings from the treatment of Alzheimer’s disease(AD).
引用
收藏
页码：165 / 174
页数：9
相关论文
共 50 条
  • [1] Estimating the Long Term Cost Savings from the Treatment of Alzheimer’s Disease: A Modelling Approach
    Peter J. Neumann
    PharmacoEconomics, 2000, 17 : 109 - 109
  • [2] Estimating long term cost savings from treatment of Alzheimer's disease - A modelling approach
    Fenn, P
    Gray, A
    PHARMACOECONOMICS, 1999, 16 (02) : 165 - 174
  • [3] Estimating the long term cost savings from the treatment of Alzheimer's disease: A modelling approach
    Neumann, PJ
    PHARMACOECONOMICS, 2000, 17 (01) : 109 - 109
  • [4] Modelling Disease Progression in Alzheimer’s DiseaseA Review of Modelling Methods used for Cost-Effectiveness Analysis
    Colin Green
    PharmacoEconomics, 2007, 25 : 735 - 750
  • [5] Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer’s DiseaseA Review with Methodological Considerations
    Anders Wimo
    Drugs & Aging, 2004, 21 : 279 - 295
  • [6] Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine
    Hauber A.B.
    Gnanasakthy A.
    Snyder E.H.
    Bala M.V.
    Richter A.
    Mauskopf J.A.
    PharmacoEconomics, 2000, 17 (4) : 351 - 360
  • [7] Potential savings in the cost of caring for Alzheimer's disease treatment with rivastigmine
    Linkins, KW
    Lloyd, LR
    Hjelmstad, GO
    Strausbaugh, HJ
    PHARMACOECONOMICS, 2000, 18 (06) : 609 - 610
  • [8] Potential savings in the cost of caring for Alzheimer's disease - Treatment with rivastigmine
    Hauber, AB
    Gnanasakthy, A
    Snyder, EH
    Bala, MV
    Richter, A
    Mauskopf, JA
    PHARMACOECONOMICS, 2000, 17 (04) : 351 - 360
  • [9] Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease
    Stefan J. Teipel
    Michael Ewers
    Veronika Reisig
    Bernd Schweikert
    Harald Hampel
    Michael Happich
    European Archives of Psychiatry and Clinical Neuroscience, 2007, 257 : 330 - 336
  • [10] Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease
    Teipel, Stefan J.
    Ewers, Michael
    Reisig, Veronika
    Schweikert, Bernd
    Hampel, Harald
    Happich, Michael
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2007, 257 (06) : 330 - 336
12345